• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Sex Differences in Atrial Fibrillation —Update on Risk Assessment, Treatment, and Long-Term Risk
AbstractPurpose of reviewAtrial fibrillation (AF) is a growing health problem worldwide. While the disease plagues both men and women, this arrhythmia does not affect both sexes equally. Women are more likely to have major adverse outcomes such as stroke and its sequela; however, recent data on stroke prevention show improving outcomes. The purpose of this review of the recent literature is to summarize important updates on risk scores and management of patients with AF.Recent findingsIt has been well known that women have a higher risk of strokes than men when untreated or when treated with warfarin. Current risk scores e...
Source: Current Treatment Options in Cardiovascular Medicine - August 27, 2018 Category: Cardiology Source Type: research

Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation: a meta-analysis
Conclusion In patients with cancer and atrial fibrillation, direct oral Xa inhibitors have a similar efficacy and may be safer compared with warfarin. These results are consistent both in patients with active cancer and history of cancer.
Source: Journal of Cardiovascular Medicine - July 30, 2020 Category: Cardiology Tags: Research articles: Arrhythmias Source Type: research

The anticoagulation dilemma and future treatment avenues in patients with breast cancer and atrial fibrillation
Atrial fibrillation (AF) is the most common arrhythmia, with a substantial rise in global incidence and prevalence. Ischemic stroke is a frequent complication of AF, since AF perfectly fulfills Virchow's triad of blood stasis, vascular damage and hypercoagulation, making oral anticoagulation (OAC) obligatory for stroke prevention. Direct oral anticoagulants (DOAC), such as dabigatran, which inhibits thrombin, and apixaban, edoxaban and rivaroxaban, which block the activated coagulation factor X (FXa), have some advantages and are largely replacing coumarin-based OAC.
Source: International Journal of Cardiology - September 30, 2020 Category: Cardiology Authors: Anke C. Fender, Dobromir Dobrev Tags: Editorial Source Type: research

Cerebral microbleeding in varicella-zoster viral meningitis: An early sign of vasculopathy?
A 75-year-old man undergoing chemotherapy for prostate cancer for 3 months presented with headache after having blisters in his left ear canal and auricle. His body temperature at presentation was 38°C. Neurologic examination revealed nuchal stiffness and left peripheral facial palsy. We also noted leukocytopenia (2,000/µL) and elevated serum C-reactive protein (8.51 mg/dL). CSF analysis showed no erythrocytes, elevated leukocytes (640/µL; 3% monocytes, 97% neutrophils), an increased protein level (473 mg/dL), and slightly decreased glucose level (51 mg/dL, serum glucose 120 mg/dL). Brain MRI and magnetic r...
Source: Neurology - March 3, 2014 Category: Neurology Authors: Ohtomo, R., Shirota, Y., Iwata, A., Shimizu, J., Tsuji, S. Tags: MRI, Other cerebrovascular disease/ Stroke, Vasculitis, Viral infections CLINICAL/SCIENTIFIC NOTES Source Type: research

Frailty syndrome: an emerging clinical problem in the everyday management of clinical arrhythmias. The results of the European Heart Rhythm Association survey
In conclusion, the complex clinical condition in frail patients presenting with arrhythmias warrants an integrated multidisciplinary approach both for the management of rhythm disturbances and for the decision on using CIEDs.
Source: Europace - October 10, 2017 Category: Cardiology Source Type: research

Anticoagulation knowledge in patients with atrial fibrillation: An Australian survey
ConclusionThe study identified knowledge gaps in patients taking OACs, and these deficiencies appeared to be greater in participants taking DOACs. Knowledge assessment should be integrated into patient counselling sessions to help identify and resolve knowledge deficits.
Source: International Journal of Clinical Practice - January 1, 2018 Category: Internal Medicine Authors: Kehinde O. Obamiro, Leanne Chalmers, Kenneth Lee, Bonnie J. Bereznicki, Luke R. E. Bereznicki Tags: ORIGINAL PAPER Source Type: research

Plant-Derived Alkaloids: The Promising Disease-Modifying Agents for Inflammatory Bowel Disease
Conclusion This paper summarizes the current findings regarding the anti-colitis activity of plant-derived alkaloids and shows how these alkaloids exhibit significant and beneficial effects in alleviating colonic inflammation. These natural alkaloids are not only promising agents for IBD treatment but are also components for developing new wonder drugs. However, the underlying molecular mechanisms or toxicological evaluation of most plant-derived alkaloids still require much scientific research, and their actual efficacies for IBD patients have not been verified well in field research. Thus, further clinical trials to elu...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news